Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.

doi:10.1093/annonc/mdn240

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Sept 2008

Zucali P A, Ruiz M G, Giovannetti E, Destro A, Varella-Garcia M, Floor K, Ceresoli G L, Rodriguez J A, Garassino I, Comoglio P, Roncalli M, Santoro A, Giaccone G

Abstract excerpt

BACKGROUND: Approximately 10% of unselected non-small-cell lung cancer (NSCLC) patients responded to the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, resistance mechanisms are not well understood. We evaluated several potential biological markers of intrinsic EGFR-TKIs-resistance in NSCLC. MATERIALS AND METHODS: pAKT, pERK, cSRC, E-cadherin, cMET[pY1003],...

Topics

Aged
Biopsy, Needle
Blotting, Western
Carcinoma, Non-Small-Cell Lung
Cohort Studies
Drug Resistance, Neoplasm
Drug Screening Assays, Antitumor
ErbB Receptors
Female
Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Gene Expression Regulation, Neoplastic

Humans

Immunohistochemistry

In Situ Hybridization, Fluorescence

Kaplan-Meier Estimate

Lung Neoplasms

Male

Middle Aged

Source

Open in PubMed Open full text

Identifiers

PMID: 18467317
DOI: 10.1093/annonc/mdn240
PMCID: PMC7360138

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-18467317-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.PMID 18467317Read ↗

Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.Semantic proximity Read ↗

Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Role of crizotinib in c-mesenchymal-epidermal transition-positive nonsmall cell lung cancer patients.Semantic proximity Read ↗

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.Semantic proximity Read ↗

cMET Exon 14 Skipping: From the Structure to the Clinic.Semantic proximity Read ↗

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft modelsSemantic proximity Read ↗

Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.